Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. (Q45976411)
scientific article
Language:
Current Data About Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
(P31) (Q13442814)
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P50) (Q30512486)
(P1545) 1
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P304) 987-993
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P407) (Q1860)

(P433) 3
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P478) 15
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P577) Saturday, March 1, 1997
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P921) (Q172341)
(P887)

(Q18936)
(P887)

(Q274160)

(P1433) (Q400292)
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P1476) "Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation." (language: en)
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

(P2093) J D Hainsworth
(P1545) 2
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

S Jeffers
(P1545) 3
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

P Miller
(P1545) 4
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

S Groshen
(P1545) 5
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

M Tan
(P1545) 6
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

L Roman
(P1545) 7
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

B Uziely
(P1545) 8
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

L Muderspach
(P1545) 9
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

A Garcia
(P1545) 10
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

A Burnett
(P1545) 11
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

F A Greco
(P1545) 12
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

C P Morrow
(P1545) 13
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

L J Paradiso
(P1545) 14
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

L J Liang
(P1545) 15
(P248)
(P698) 9060537
(P813) Monday, December 18, 2017
(P854) http://europepmc.org/abstract/MED/9060537

other details
description scientific article

External Links
(P356) 10.1200/JCO.1997.15.3.987
(P698) 9060537